Summary of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Ratings on Dec 8, 2018

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Corporate Logo
During Q2 2018 the big money sentiment decreased to 1.89. That’s change of 0.55, from 2018Q1’s 2.44. 16 investors sold all, 12 reduced holdings as Dicerna Pharmaceuticals, Inc. ratio is negative. 18 rose stakes while 35 funds acquired stakes. Funds hold 36.31 million shares thus 18.35% more from 2018Q1’s 30.68 million shares.
Piedmont Invest Advisors Limited Co invested in 0% or 771 shs. 12,807 are owned by Quantbot Technologies Limited Partnership. Birchview Cap L P accumulated 0.37% or 45,000 shs. Bancorp Of Montreal Can, a Ontario – Canada-based fund reported 73,316 shs. Alliancebernstein Lp owns 12,600 shs. Citadel Advisors Ltd Llc holds 1.71M shs or 0.01% of its capital. Moreover, Adage Cap Partners Gp Limited Liability Co has 0.07% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Metropolitan Life Ins Ny owns 15,333 shs. Emory University invested in 1.46% or 179,568 shs. Vanguard Grp Inc has invested 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). New York-based Ghost Tree Capital Limited Liability Company has invested 2.38% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Bnp Paribas Arbitrage Sa owns 0% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 1,606 shs. Renaissance Technologies Ltd has 0% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). California State Teachers Retirement System has invested 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Northern holds 466,278 shs or 0% of its capital.

Dicerna Pharmaceuticals, Inc. had 4 sales and 0 insider buys since August 15, 2018. This’s net activity of $12.83 million. On Wednesday, August 15 LANGER DENNIS had sold 38,341 shs worth $613,456. On Wednesday, September 5 a trade for 2,301 shs valued at $40,268 was made by Weissman James B.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Ratings Coverage

In total 5 analysts cover Dicerna Pharmaceuticals (NASDAQ:DRNA). “Buy” rating has 5, “Sell” are 0, while 0 are “Hold”. (NASDAQ:DRNA) has 100% bullish analysts. 7 are the (NASDAQ:DRNA)’s ratings reports on Dec 8, 2018 according to StockzIntelligence Inc. On Monday, September 17 FBR Capital maintained Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) rating. FBR Capital has “Neutral” rating and $13.5 target. The company rating was upgraded by FBR Capital on Tuesday, November 6. On Thursday, August 9 the stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) earned “Buy” rating by Stifel Nicolaus. On Wednesday, August 15 the stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has “Buy” rating given by H.C. Wainwright. On Tuesday, October 30 Citigroup maintained Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) with “Buy” rating. Listed here are Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) PTs and latest ratings.

28/11/2018 Broker: Leerink Swann Rating: Outperform New Target: $24 Initiates Coverage On
06/11/2018 Broker: FBR Capital Old Rating: Neutral New Rating: Buy Old Target: $13.5 New Target: $21 Upgrade
30/10/2018 Broker: Citigroup Old Rating: Buy New Rating: Buy Old Target: $27 New Target: $30 Maintain
17/09/2018 Broker: FBR Capital Old Rating: Neutral New Rating: Neutral Old Target: $10 New Target: $13.5 Maintain
13/09/2018 Broker: Citigroup Rating: Buy New Target: $27 Initiates Coverage On
15/08/2018 Broker: H.C. Wainwright Old Rating: Neutral New Rating: Buy Upgrade
09/08/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Buy Old Target: $18 New Target: $20 Maintain

DRNA touched $12.74 during the last trading session after $1.22 change.Currently Dicerna Pharmaceuticals, Inc. is uptrending after 325.07% change in last December 8, 2017. DRNA has also 393,230 shares volume. The stock outperformed the S&P 500 by 309.45%.

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for rare, chronic liver, cardiovascular, and viral infectious diseases in the United States and internationally.The company has $799.20 million market cap. The companyÂ’s preclinical stage development programs include DCR-PHXC for the treatment of primary hyperoxaluria type 1; DCR-PCSK9, which targets the PCSK9 gene in the treatment of statin-refractory patients with hypercholesterolemia; and DCR-HBV for the treatment of chronic hepatitis B virus infection, as well as other product candidates for use in the treatment of cardiovascular and chronic liver diseases.Last it reported negative earnings. It has a research collaboration and license agreements with Kyowa Hakko Kirin Co., Ltd.; City of Hope, an academic research and medical center; and Plant Bioscience Limited.

For more Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) news released briefly go to:,,, or The titles are as follows: “Dicerna Pharmaceuticals, Inc. (DRNA) CEO Douglas Fambrough on Q2 2018 Results – Earnings Call Transcript – Seeking Alpha” released on August 08, 2018, “Dicerna prices follow-on common stock offering – Seeking Alpha” on September 07, 2018, “Citi soft on Solid Biosciences in premarket healthcare analyst action – Seeking Alpha” with a publish date: November 06, 2018, “Chardan: After Dicerna Pharma (NASDAQ:DRNA)’s 370% Run, Wait For Better Entry Point – Benzinga” and the last “Dicerna Pharmaceuticals: Institutional Buying Heats Up – Seeking Alpha” with publication date: February 19, 2018.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.